At March’s online “Racjonalny Inwestor” conference hosted by StockWatch.pl, our CEO, Wojciech Kula, joined a panel discussion on a key question: how do clinical trial strategies affect a biotech company’s investment appeal?
Wojciech shared the stage with experts from Noble Securities, Navigator Capital, and Bioceltix, discussing how strong clinical results and transparent trial execution build investor confidence.
The session, open and free to all investors, took place on October 15 and underscored the message: in today’s market, robust scientific evidence isn’t just a regulatory milestone—it’s a competitive advantage.
Explore why a well-designed, efficiently run clinical program is among the most powerful tools for enhancing market perception and supporting long-term growth. Watch the recording of the panel here (in Polish).
We’re pleased to announce a strategic partnership between Axcellant and Prometheus MedTech.AI — a medtech startup developing AI-powered solutions for…
The Axcellant team has returned from the European Association of Nuclear Medicine (EANM) Annual Congress in Barcelona — and it’s…
The robust development of nuclear medicine depends on the availability of radioactive isotopes, some of which are used for diagnostic…
Copyright @ 2026 Axcellant